Edinburgh Research Explorer

Inhibition of group I metabotropic glutamate receptors reverses autistic-like phenotypes caused by deficiency of the translation repressor eIF4E binding protein 2

Citation for published version:

Digital Object Identifier (DOI):
10.1523/JNEUROSCI.4615-14.2015

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Neuroscience

Publisher Rights Statement:
Available to the public to copy, distribute, or display under a Creative Commons Attribution 4.0 International (CC BY 4.0) license.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2

Argel Aguilar-Valles,1,2 Edna Matta-Camacho,2 Arkady Khoutorsky,2 Christos Gkogkas,2,4 Karim Nader,3 Jean-Claude Lacaille,1,* and Nahum Sonenberg2*

1Department of Neurosciences and Groupe de Recherche sur le Système Nerveux Central, Université de Montréal, Montréal, Québec H3C 3J7, Canada, 2Department of Biochemistry and Goodman Cancer Centre, McGill University, Montréal, Québec H3A 1A3, Canada, 3Department of Psychology, McGill University, Montréal, Québec H3A 1B1, Canada, and 4Patrick Wild Centre and Centre for Integrative Physiology, University of Edinburgh, Edinburgh EH8 9XD, United Kingdom

Exacerbated mRNA translation during brain development has been linked to autism spectrum disorders (ASDs). Deletion of the eukaryotic initiation factor 4E (eIF4E)-binding protein 2 gene (Eif4ebp2), encoding the suppressor of mRNA translation initiation 4E-BP2, leads to an imbalance in excitatory-to-inhibitory neurotransmission and ASD-like behaviors. Inhibition of group I metabotropic glutamate receptors (mGlurRs) mGlur1 and mGlur5 reverses the autistic phenotypes in several ASD mouse models. Importantly, these receptors control synaptic physiology via activation of mRNA translation. We investigated the potential reversal of autistic-like phenotypes in Eif4ebp2−/− mice by using antagonists of mGlur1 (JNJ16259685) or mGlur5 (fenobam). Augmented hippocampal mGlur-induced long-term depression (LTD; or chemically induced mGlur-LTD) in Eif4ebp2−/− mice was rescued by mGlur1 or mGlur5 antagonists. While rescue by mGlur5 inhibition occurs through the blockade of a protein synthesis-dependent component of LTD, normalization by mGlur1 antagonists requires the activation of protein synthesis. Synaptically induced LTD was deficient in Eif4ebp2−/− mice, and this deficit was not rescued by group I mGlur antagonists. Furthermore, a single dose of mGlur1 (0.3 mg/kg) or mGlur5 (3 mg/kg) antagonists in vivo reversed the deficits in social interaction and repetitive behaviors (marble burying) in Eif4ebp2−/− mice. Our results demonstrate that Eif4ebp2−/− mice serve as a relevant model to test potential therapies for ASD symptoms. In addition, we provide substantive evidence that the inhibition of mGlur1/mGlur5 is an effective treatment for physiological and behavioral alterations caused by exacerbated mRNA translation initiation.

Key words: autism spectrum disorders; group I mGlurRs; long-term depression; repetitive behavior; social interaction; translation initiation

Exacerbated mRNA translation during brain development is associated with several autism spectrum disorders (ASDs). We recently demonstrated that the deletion of a negative regulator of mRNA translation initiation, the eukaryotic initiation factor 4E-binding protein 2, leads to ASD-like behaviors and increased excitatory synaptic activity. Here we demonstrated that autistic behavioral and electrophysiological phenotypes can be treated in adult mice with antagonists of group I metabotropic glutamate receptors (mGlurRs), which have been previously used in other ASD models (i.e., fragile X syndrome). These findings support the use of group I mGlur antagonists as a potential therapy that extends to autism models involving exacerbated mRNA translation initiation.

Introduction

Autism spectrum disorders (ASDs) are thought to be caused by an imbalance in the ratio of excitatory-to-inhibitory (E/I) neurotransmission due to impaired neurodevelopment (Kelleher and Bear, 2008). Several single-gene disorders, harboring mutations upstream of the mammalian target of rapamycin (mTOR) complex 1 (mTORC1), manifest high rates of autism and are...
characterized by increased cap-dependent mRNA translation of synaptic proteins (Kelleher and Bear, 2008). These disorders include tuberous sclerosis complex (Curatolo et al., 2010) and PTEN (phosphatase and tensin homolog) hamartoma tumor syndrome (Butler et al., 2005).

mTORC1 activates cap-dependent translation via phosphorylation and inactivation of the eukaryotic initiation factor 4E (eIF4E) binding proteins (4E-BPs; Gingras et al., 1999). eIF4E is the cap-binding component of the eIF4E complex, which also contains the RNA helicase, eIF4A, and the modular scaffolding protein eIF4G, which bridges the mRNA to the ribosome. 4E-BPs repress translation initiation by binding to eIF4E and preventing the eIF4E–eIF4G interaction, thereby inhibiting eIF4E complex formation. There are three 4E-BP isoforms, of which 4E-BP2 is the predominant form in the brain (Tsukiyama-Kohara et al., 2001; Banko et al., 2005).

Recently, we (Gkogkas et al., 2013 and Santini et al. (2013) demonstrated that excessive eIF4E activity promotes the development of ASD-like behaviors in mice. Genetic deletion of If4ebp2 (encoding 4E-BP2) or overexpression of Eif4e resulted in augmented translation of mRNAs encoding for neureligins, engendering an imbalance in the E/I ratio, impaired social interaction, repetitive behaviors, and vocalization defects (Gkogkas et al., 2013; Santini et al., 2013).

Group I metabotropic glutamate receptors (mGlurs), comprising mGluR1 and mGluR5, have been explored as a therapeutic target for fragile X syndrome (FXS; Bear et al., 2004) and other disorders with autistic features (Tian et al., 2015). FXS is a genetic disorder with a high prevalence of autism caused by the loss of the negative regulator of mRNA translation FMR1 (Weiler et al., 1997). In Fmr1-null mice, mGluR1/mGluR5 activation induces exacerbated hippocampal long-term depression (mGluR-LTD; Huber et al., 2002; Hou et al., 2006; Nosyreva and Huber, 2006). mGluR-LTD is dependent on de novo protein synthesis (Weiler and Greenough, 1993; Huber et al., 2000), and involves the activation of mTORC1 and cap-dependent translation (Hou and Klann, 2004; Banko et al., 2006; Antion et al., 2008). Importantly, mGluR-dependent LTD is also exacerbated in Eif4ebp2-null mice (Banko et al., 2006); thus, inhibition of group I mGluRs could benefit ASD caused by dysregulated cap-dependent translation initiation. We sought to determine whether mice lacking 4E-BP2 could serve as a useful model to investigate therapies aimed to improve decreased social interaction and repetitive behaviors. Consequently, we determined whether mGluR1 or mGluR5 antagonists could rescue the synaptic and behavioral deficits in Eif4ebp2 knock-out mice.

Materials and Methods

Eif4ebp2 knock-out mice were previously described (Banko et al., 2005). Male littermates from heterozygote crossings were housed in temperature-controlled (21°C) and humidity-controlled (~55%) rooms, with ad libitum food and water, and a 12 h light/dark cycle. All procedures were conducted in compliance with the Canadian Council on Animal Care guidelines and were approved by the McGill University and Université de Montréal Animal Care Committees. Electrophysiology: Transverse hippocampal slices (400 μm thickness), prepared from 30- to 35-d-old male mice, were allowed to recover for at least 2 h at 32°C submerged in oxygenated artificial CSF (ACSF; 124 mM NaCl, 3 mM KCl, 1.25 mM NaH₂PO₄, 2 mM MgSO₄, 2 mM CaCl₂, 26 mM NaHCO₃, and 10 mM glucose) and were perfused with ACSF for an additional 30 min in a recording chamber at 27–28°C. Field EPSPs (fEPSPs) were recorded in CA1 stratum radiatum with glass electrodes (2–3 MΩ) filled with ASCF. Schaffer collateral fEPSPs were evoked with a concentric bipolar tungsten stimulating electrode placed in mid-stratum radiatum proximal to the CA3 region. Baseline stimulation was applied at 0.033 Hz by delivering 0.1 ms pulses, with intensity adjusted to evoke fEPSPs with 60% of maximal amplitude. For chemically induced mGluR-LTD, CA1 and CA3 hippocampal regions were isolated by a surgical cut before recovery, and group 1 mGluR agonist (S)-3,5-dihydroxyphosphorylencephalin (DHPG; 50 μM; Tocris Bioscience) was added to ACSF for 10 min for induction. For synaptically induced LTD, paired-pulse low-frequency stimulation (PP-LFS) was performed as reported (Huber et al., 2000; Volk et al., 2006). PP-LFS stimulation (50 ms inter-stimulus interval) was administered at 1 Hz for 20 min in the presence of the NMDAR antagonist aminophosphonovalerate (50 μM). fEPSP slope measurements were performed on digitized analog recordings using the Clampfit analyze function. The slope was measured at between 10% and 90% of maximal fEPSP amplitude during an epoch defined by constant cursor placements, which excluded fiber volley and population spikes. Where indicated, we used anisomycin (40 μM; Tocris Bioscience) 20 min prior to drug injection. Male wild-type C57BL/6J mice, containing 5-cm-deep fresh bedding with 20 black marbles prearranged, were treated with the chosen doses of each antagonist (0.3 mg/kg for Eif4ebp2−/− mice was treated with the chosen doses of each antagonist (0.3 mg/kg for J16259685; 3 mg/kg for fenobam) or vehicle, and 30 min or 24 h after, brains were collected, hippocampi were isolated, flash frozen, and used later for Western blotting.

In vivo experiments. To assess the concentration of fenobam or J16259685 that had no effect on the social behavior of wild-type mice, 7-week-old wild-type C57BL/6J mice were treated with vehicle [30% DMSO in 0.9% NaCl; 8 ml/kg body weight (BW), i.p.], J16259685 (0.3 or 1 mg/kg BW) and tested 30 min later. After determining the concentrations that spared social behavior in wild-type mice, a different cohort of wild-type and Eif4ebp2−/− mice was treated with the chosen doses of each antagonist (0.3 mg/kg for J16259685; 3 mg/kg for fenobam) or vehicle, and 30 min or 24 h after, brains were collected, hippocampi were isolated, flash frozen, and used later for Western blotting.

In separate experiments, Eif4ebp2−/− mice and wild-type littermates were treated with vehicle and tested for social interaction 30 min after injection. One week after, mice were treated with either J16259685 or fenobam and tested again for social interaction 30 min after injection. Twenty-four hours after treatment, mice were treated with either an mGluR5 antagonist (0.9 μM; Tocris Bioscience), or J16259685, an mGluR1 antagonist (6 μM; Tocris Bioscience) 10 min prior to, during, and for 5 min after LTD induction.

In vivo experiments. To assess the concentration of fenobam or J16259685 that had no effect on the social behavior of wild-type mice, 7-week-old wild-type C57BL/6J mice were treated with vehicle [30% DMSO in 0.9% NaCl; 8 ml/kg body weight (BW), i.p.], J16259685 (0.3 or 1 mg/kg BW) and tested 30 min later. After determining the concentrations that spared social behavior in wild-type mice, a different cohort of wild-type and Eif4ebp2−/− mice was treated with the chosen doses of each antagonist (0.3 mg/kg for J16259685; 3 mg/kg for fenobam) or vehicle, and 30 min or 24 h after, brains were collected, hippocampi were isolated, flash frozen, and used later for Western blotting.

In separate experiments, Eif4ebp2−/− mice and wild-type littermates were treated with vehicle and tested for social interaction 30 min after injection. One week after, mice were treated with either J16259685 or fenobam and tested again for social interaction 30 min after injection. Twenty-four hours after treatment, mice were treated with either an mGluR5 antagonist (0.9 μM; Tocris Bioscience), or J16259685, an mGluR1 antagonist (6 μM; Tocris Bioscience) 10 min prior to, during, and for 5 min after LTD induction.

in vivo experiments. To assess the concentration of fenobam or J16259685 that had no effect on the social behavior of wild-type mice, 7-week-old wild-type C57BL/6J mice were treated with vehicle [30% DMSO in 0.9% NaCl; 8 ml/kg body weight (BW), i.p.], J16259685 (0.3 or 1 mg/kg BW) and tested 30 min later. After determining the concentrations that spared social behavior in wild-type mice, a different cohort of wild-type and Eif4ebp2−/− mice was treated with the chosen doses of each antagonist (0.3 mg/kg for J16259685; 3 mg/kg for fenobam) or vehicle, and 30 min or 24 h after, brains were collected, hippocampi were isolated, flash frozen, and used later for Western blotting.
used were anti-mouse and anti-rabbit (GE Healthcare). Quantification of immunoblots was performed using ImageJ (National Institutes of Health). Values were normalized to GAPDH and expressed as a ratio of pS6/tS6/GAPDH.

Statistical analysis. All data are presented as the mean ± SEM. Electrophysiology, Western blotting, and marble-burying test data were analyzed using a two-way ANOVA (using genotype and treatment as between-subjects factors), except for mGluR-LTD data from Eif4ebp2+/− mice which used a two-way ANOVA (using genotype and treatment as between-subjects factors), and marble-burying test data were analyzed using repeated-measures ANOVA (using time in chamber as the within-subject factor) independently for each treatment. So-cial preference data (see Fig. 3) were analyzed using a two-way ANOVA (using genotype and treatment as between-subjects factors) and with chamber used as the within-subject factor; each time point (baseline, 0.5, and 24 h after treatment) were analyzed independently as no comparisons between these were intended. When the main factor or interaction of an ANOVA was significant, analysis was followed by Bonferroni-corrected pairwise comparisons. p values <0.05 were deemed significant.

Results

Exacerbated group I mGluR-dependent LTD is rescued by inhibition of mGluR1/mGluR5

We first tested the effect of mGluR1 or mGluR5 antagonists on exacerbated mGluR-LTD in Eif4ebp2−/− mice. As previously reported (Banko et al., 2006), DHPG-induced LTD in the CA1 region of the hippocampus was significantly exacerbated in Eif4ebp2−/− mice (Eif4ebp2+/− vs Eif4ebp2−/− vehicle; F(1,119) = 10.01, p = 0.002; Fig. 1A, E). In wild-type mice, hippocampal mGluR-LTD induction is dependent on the activation of both mGluR1 and mGluR5, and pharmacological inhibition of only one of these receptors during induction is not sufficient to block mGluR-LTD (Hou and Klann, 2004; Volk et al., 2006). Accordingly, incubation with either JNJ16259685 (mGluR1) or fenobam (mGluR5) in Eif4ebp2−/− mice did not affect mGluR-LTD (F(3,119) = 5.31, p = 0.002, vehicle vs JNJ16259685 or fenobam, p = 1.0; Fig. 1B, C, E). In contrast, in Eif4ebp2−/− mice, JNJ16259685 and fenobam reduced mGluR-LTD (F(3,119) = 9.46, p = 0.0009; vehicle vs JNJ16259685, p = 0.0019; vehicle vs fenobam, p = 0.001; Fig. 1B, C, E) to control levels for JNJ16259685 or to a greater degree than control levels for fenobam. These results demonstrate a greater sensitivity of hippocampal mGluR-LTD in Eif4ebp2−/− mice to the inhibition of either mGluR1 or mGluR5, which results in the rescue of synaptic plasticity deficits caused by increased cap-dependent translation initiation.

To determine the relationship between the rescued mGluR-LTD in Eif4ebp2−/− mice and protein synthesis, we treated hippocampal slices with the protein synthesis inhibitor anisomycin, alone or in combination with either JNJ16259685 or fenobam (Fig. 1B–E). As expected, anisomycin completely inhibited hippocampal mGluR-LTD in wild-type mice (Eif4ebp2+/− vs anisomycin, p = 0.002; Fig. 1D, E), while...
restoring the mGluR-LTD in Eif4ebp2−/− mice to control levels (Eif4ebp2−/− vehicle vs anisomycin; p = 0.014; Fig. 1D,E). This effect indicates that in Eif4ebp2-null mice LTD is still partially dependent on de novo protein synthesis and is similar to the normalization of CA1 LTP by anisomycin or cycloheximide in Eif4ebp2−/− mice (Banko et al., 2005). Co-treatment of hippocampal slices of Eif4ebp2-null mice with anisomycin and JNJ16259685 abrogated the ability of each drug to rescue mGluR-LTD when applied individually, resulting in mGluR-LTD levels that were significantly lower than those in the group of JNJ16259685-treated Eif4ebp2−/− mice (Fig. 1B,E; Eif4ebp2−/− plus JNJ16259685 vs Eif4ebp2−/− plus JNJ16259685 and anisomycin; t120 = 5.05, p = 0.0009) and were comparable to those of DHPG-treated Eif4ebp2−/− mice. Thus, the rescue of exaggerated LTD by mGluR1 antagonism requires protein synthesis. In contrast, the rescued mGluR-LTD by fenobam was insensitive to anisomycin treatment (Fig. 1C,E; Eif4ebp2−/− plus fenobam vs Eif4ebp2−/− plus fenobam and anisomycin; t107 = 0.06, p = 0.95). Given that both anisomycin and fenobam reduce the exaggerated mGluR-LTD in Eif4ebp2−/− mice when applied individually, the lack of an additive effect when coadministered suggests an occlusion of the rescue effect, and that fenobam acts by reducing the protein synthesis-sensitive component of the exaggerated mGluR-LTD in Eif4ebp2−/− mice.

Synaptically elicited LTD is deficient in Eif4ebp2−/− and not rescued by group I mGluR antagonists

Protein synthesis-dependent LTD can be induced in CA1 by using PP-LFS of Schaffer collaterals (Huber et al., 2000). This form of plasticity requires the activation of muscarinic acetylcholine receptors, in addition to group I mGluRs (Volk et al., 2007). We determined whether the induction of PP-LFS LTD was altered in Eif4ebp2−/− mice and found that it was impaired (effect of genotype: F(1,88) = 14.42, p = 0.0009; Fig. 2A,D), suggesting a differential role of 4E-BP2 in chemically and synaptically induced LTD in the hippocampus.

We then examined whether mGluR1 or mGluR5 antagonists could rescue the impaired LTD in Eif4ebp2−/− mice. JNJ16259685 or fenobam, at the doses that rescued chemically induced mGluR-LTD, failed to normalize the deficit in LTD (effect of treatment: F(2,48) = 0.68, p = 0.51; Fig. 2B,C) and did not affect PP-LFS LTD in controls (Fig. 2B–D). These results are not surprising, since the role of group I mGluRs in LTD induced by PP-LFS is complex, seemingly secondary to muscarinic receptor activation in the hippocampus (Volk et al., 2006, 2007).

JNJ16259685 and fenobam rescue social interaction and repetitive behaviors

To investigate the effect of JNJ16259685 and fenobam on social interaction and repetitive behaviors in Eif4ebp2−/− mice, we first established the maximal tolerable dose of each antagonist that does not impair social behavior in wild-type mice. JNJ16259285 and fenobam had no effect at the lower dose [Stranger (S) vs Empty (E) chamber: 0.3 mg/kg JNJ16259285, p = 0.03; 3 mg/kg fenobam, p = 0.007; Fig. 3A] but impaired social preference at the higher dose (S vs E; p = 1.0 for 1 and 10 mg/kg, respectively; Fig. 3A). We verified that the antagonists reduced signaling downstream of group I mGluRs at the lowest doses used, using pS6 at the Ser235/236 as the readout for mTORC1 and MAPK/ERK activation (Thomas, 2002). Both antagonists reduced pS6 in the hippocampus of wild-type mice 30 min after their administration (F(4,60) = 7.46, p = 0.0009; vehicle vs JNJ16259285 at 0.5 h, p = 0.003; vehicle vs fenobam at 0.5 h, p = 0.012; Fig. 3B). This reduction was transient, as levels returned to baseline 24 h after the injection of either antagonist (vehicle vs JNJ16259285 or fenobam at 24 h, p = 1.0; Fig. 3B). S6 phosphorylation occurs in parallel with that of the 4E-BPs, downstream of mTOR (Gingras et al., 1999); thus, it may not necessarily correlate with increased translation in Eif4ebp2−/− mice. Indeed, in Eif4ebp2−/− mice pS6 levels were comparable to those of wild-type mice (F(1,60) = 0.15, p = 0.70; Fig. 3B), but JNJ16259285 and fenobam failed to significantly reduce the levels of pS6, 30 min after injection (F(1,60) = 3.91, p = 0.007; vehicle vs JNJ16259285 or fenobam at 0.5 h, p = 1.0; Fig. 3B). One potential reason for this discrepancy is that increased levels of network activity in baseline conditions in Eif4ebp2-null mice (Bidinosti et al., 2010; Gkogkas et al., 2013) could mask the contribution of mGluR1 and 5 on S6 phosphorylation.

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Synaptically induced LTD is impaired in Eif4ebp2−/− mice and unresponsive to group I mGluR antagonists. A, PP-LFS induced a stable LTD in wild-type mice, while it was completely absent in Eif4ebp2−/− mice. B, PP-LFS LTD was not affected by incubation with JNJ16259285 in wild-type mice. Similarly, the impairment in this form of LTD in Eif4ebp2−/− mice was not changed by the mGluR1 antagonist. C, The mGluR5 antagonist fenobam did not affect the response to PP-LFS in either wild-type or Eif4ebp2−/− mice. D, iEPSP slope at 70–90 min after PP-LFS onset for Eif4ebp2−/− (n = 12), Eif4ebp2−/− plus JNJ16259285 (n = 7), Eif4ebp2−/− plus fenobam (n = 7), Eif4ebp2−/− (n = 10), Eif4ebp2−/− plus JNJ16259285 (n = 8), and Eif4ebp2−/− plus fenobam (n = 12). Insets in A–C are representative traces. Calibration: 50 ms and 0.5 mV. **p < 0.001.
Figure 3. Effects of mGluR1 and mGluR5 antagonists on social interaction and mTORC1 signaling in wild-type mice. A, JNJ16259285 and fenobam impaired social preference at the higher doses (1 mg/kg for JNJ16259285 and 10 mg/kg for fenobam), but not at lower doses (0.3 mg/kg for JNJ16259285 and 3 mg/kg for fenobam; vehicle-treated mice, n = 20; for all other groups, n = 7, C, Center). B, At doses that did not affect the social preference, JNJ16259285 and fenobam were effective in reducing S6 ribosomal protein phosphorylation in the hippocampus of wild-type mice but not in Elf4ebp2-null mice. Twenty-four hours after injection, the short-term effect of JNJ16259285 and fenobam disappeared in wild-type mice, but fenobam had a delayed effect in reducing pS6 in 4E-BP2 knock-out mice; representative Western blots are presented in the top (asterisk indicates a residual signal of the anti-tS6 antibody when probing for GAPDH). Elf4ebp2+/− mice exhibited a significant improvement in social approach (S vs E chamber: F(1,37) = 7.05, p = 0.012; Elf4ebp2+/− vs S chamber, p = 0.0009; Elf4ebp2+/− vs Elf4ebp2−/− S chamber, p = 0.036; Elf4ebp2+/− S vs Elf4ebp2−/− S chamber, p = 0.25; Fig. 4B). We then administered JNJ16259285 or fenobam to Elf4ebp2−/− or wild-type littermates. As reported above (Fig. 3A), neither of these drugs had a significant effect on the social preference exhibited by Elf4ebp2−/− mice (0.5 h: F(2,33) = 20.76, p = 0.0009; S vs E chamber, p = 0.045 (Fig. 4A); F(1,34) = 36.46, p = 0.0009; S vs E chamber, p = 0.0009 (Fig. 4B)). Importantly, JNJ16259285 rescued the deficit in social approach of Elf4ebp2−/− mice (0.5 h: S vs E chamber, p = 0.011 (Fig. 4A); S vs E cage, p = 0.0009 (Fig. 4B)), albeit transiently, because the rescue was not observed 24 h after JNJ16259285 application (24 h: F(2,33) = 37.48, p = 0.0009; S vs E chamber, p = 1.0 (Fig. 4A); F(1,37) = 20.02, p = 0.0009 S vs E chamber, p = 0.09 (Fig. 4B)). Fenobam did not affect the impaired social interaction in Elf4ebp2−/− mice 0.5 h after injection (S vs E chamber: p = 1.0, Fig. 4A; p = 0.2, Fig. 4B). However, Elf4ebp2−/− mice exhibited a significant improvement in social approach 24 h after fenobam treatment (S vs E chamber, p = 0.023; Fig. 4A,B). The latter result parallels our finding that fenobam caused a significant reduction in pS6 levels 24 h after fenobam administration (but not at 0.5 h; Fig. 3B). Thus, despite differences in the time course, inhibition of either mGluR1 or mGluR5 rescues the impaired social interaction caused deficient 4E-BP2.
We also investigated whether JNJ16259285 and fenobam could reverse the augmented marble-burying behavior in 
Eif4ebp2$^{-/-}$ mice. In wild-type mice, JNJ16259285 and fenobam did not affect the number of marbles buried (genotype × drug interaction: $F_{(2,63)}$, $p = 0.012$; Eif4ebp2$^{+/+}$ vehicle vs fenobam, $p = 1.0$; or vehicle vs JNJ16259285, $p = 0.85$; Fig. 4C). In the Eif4ebp2$^{-/-}$ mice, the increased number of marbles buried (Eif4ebp2$^{+/+}$ vehicle vs Eif4ebp2$^{-/-}$ vehicle, $p = 0.0009$) was reversed to control levels by treatment with JNJ16259285 or fenobam (Eif4ebp2$^{-/-}$ JNJ16259285 or Eif4ebp2$^{-/-}$ fenobam vs Eif4ebp2$^{-/-}$ vehicle, $p = 0.0009$). Thus, the inhibition of either mGluR1 or mGluR5 rescues the enhanced repetitive behavior phenotype caused by enhanced cap-dependent mRNA translation.

**Discussion**

Here, we demonstrated that in Eif4ebp2$^{-/-}$ mice, the inhibition of mGluR1 or mGluR5 rescued exaggerated mGluR-LTD (Fig. 1), as well as impaired social interaction and repetitive marble burying (Fig. 4), while leaving unaltered the impaired PP-LFS LTD (Fig. 2). Importantly, the doses required to rescue synaptic physiology and behavior in Eif4ebp2-null mice had no effect in wild-type mice (Figs. 1, 2, 3, 4). These results establish the Eif4ebp2-null mouse as a tool for the testing of mGluR1/mGluR5 antagonists as candidate drugs to treat ASD and cognitive impairment.

Genetic or pharmacological mGluR5 inhibition rescues autistic and cognitive phenotypes in mouse and Drosophila FXS models (Aschrafi et al., 2005; Chuang et al., 2005; McBride et al., 2005; Yan et al., 2005; Dölen et al., 2007; Osterweil et al., 2010; Levens et al., 2011). mGluR5 inhibition is also effective in other ASD models, including BTBR mice (Silverman et al., 2010, 2012), which model a microdeletion on the human chromosome 16p11.2 (Tian et al., 2015), and in ASD-like alterations caused by prenatal exposure to the anticonvulsant drug valproic acid (Mehta et al., 2011). These successful preclinical studies led to the implementation of clinical trials with mGluR5 antagonists in FXS. An early open-label clinical trial with fenobam showed an improvement in the general anxiety level and in prepulse inhibition, without safety concerns in FXS (Berry-Kravis et al., 2009), but this was not followed up by further trials (Scharf et al., 2015). Other mGluR5 antagonists (AFQ056, Novartis; STX101, Seaside Therapeutics; RO4917523, Roche) also had initial successes, yet more recently failed to show significant symptomatic improvement compared with placebo in patients (Healy et al., 2011; Jacquemont et al., 2011; Gross et al., 2012; Scharf et al., 2015). The compound AFQ056 appeared to improve the behavioral outcome in FXS patients with fully methylated alleles (and no detectable FMR1 mRNA), but not in those with partial methylation (Jacquemont et al., 2011), suggesting that the underlying genetic variability may be important for the responsiveness to treatment.

Our current study shows that the therapeutic effect of mGluR5 inhibition with fenobam is also evident in a model where cap-dependent translation initiation is augmented. Additionally, we demonstrated that mGluR1 is also a promising drug target. In this regard, both fenobam and JNJ16259285 were equally potent in rescuing exacerbated chemically induced mGluR-LTD, and increased marble burying, although they differed in the time course of their beneficial effect on impaired social interaction and on phosphorylation levels of hippocampal S6. The reason for the delayed effect of fenobam is unclear, as antagonists of mGluR5 (MPEP or GRN-529) have a short-term antinociceptive effect, and the delayed effect of fenobam is also evident in a model where mGluR1 is a promising drug target. In this regard, both fenobam and JNJ16259285 were equally potent in rescuing exacerbated chemically induced mGluR-LTD, and increased marble burying, although they differed in the time course of their beneficial effect on impaired social interaction and on phosphorylation levels of hippocampal S6. The reason for the delayed effect of fenobam is unclear, as antagonists of mGluR5 (MPEP or GRN-529) have a short-term antinociceptive effect, and the delayed effect of fenobam is also evident in a model where mGluR1 is a promising drug target.
effect on social interaction in other ASD models (Silverman et al., 2010, 2012; Mehta et al., 2011).

Eif4ebp2<sup>−/−</sup> mice are more sensitive, at the electrophysiological and behavioral level, than their wild-type littermates to the effects of mGluR1/mGluR5 antagonists. The mechanism for this increased sensitivity is not straightforward, but may involve MAPK/ERK signaling (Banko et al., 2006). Given that altered hippocampal plasticity in Eif4ebp2<sup>−/−</sup> mice still depends, at least partly, on translation (Fig. 1D; Banko et al., 2005, 2006), the ERK-MNK1/2-eIF4E pathway may be important in the therapeutic effect of mGluR1/mGluR5 antagonists. In addition, our results showed that mGluR5 inhibition exerted its rescue in Eif4ebp2<sup>−/−</sup> mice via the regulation of protein synthesis, downstream of the initiation step. Accordingly, group I mGluRs can regulate elongation (Park et al., 2008) and reactivation of stalled ribosomes (Graber et al., 2013). In contrast, the rescue of mGluR-LTD by mGluR1 antagonist JNJ16259285 requires protein synthesis activation. One potential explanation for the differential requirement of protein synthesis by mGluR1 and mGluR5 is that each receptor may involve different cellular substrates. For example, mGluR1 is enriched in CA1 oriens-alveus interneurons (Baude et al., 1993; Ran et al., 2009). Therefore, inhibition by JNJ16259285 may preferentially affect this subpopulation of interneurons and indirectly impact pyramidal cell function. In contrast, mGluR5 appears to be localized on the neurites of pyramidal neurons in the hippocampus (López-Bendito et al., 2002) and therefore directly impact their function.

Synaptically induced LTD was completely absent in Eif4ebp2<sup>−/−</sup> mice, indicating that the control of cap-dependent mRNA translation through 4E-BP2 is necessary for its induction. In this regard, the absence of 4E-BP2 may result in increased levels of an endogenous inhibitor of synthetically induced LTD, or an occlusion of induction due to the saturation of endogenous mechanisms. Our findings indicate a critical, yet distinct, involvement of 4E-BP2 regulation of cap-dependent mRNA translation in synthetically and chemically induced LTD.

Our results clearly indicate that enhanced signaling through group I mGluRs plays a role in the pathophysiology induced by the absence of 4E-BP2, a key repressor of cap-dependent translation initiation in the brain. Consequently, antagonists of mGluR1 or mGluR5 may be candidates for drugs to correct deficits in synaptic plasticity and behavior relevant for ASD due to dysregulated eIF4E-dependent translation.

References


